Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03305445
Title Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai

diffuse large B-cell lymphoma


Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.